Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Zenapax/CellCept combo trial to seek superiority to cyclosporine, PDL says.

Executive Summary

ROCHE CELLCEPT/ZENAPAX STUDY BEING TOUTED AS "CYCLOSPORINE ELIMINATION" TRIAL, Zenapax innovator Protein Design Labs President Jon Saxe told analysts at a Paine Webber meeting in New York June 4. Roche has "initiated very recently a study of CellCept [mycophenylate mofetil] and Zenapax [dacliximab] versus cyclosporine with the thought that you could replace cyclosporine with this combination, get at least a result with far better patient safety" without the nephrotoxicity of cyclosporine.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel